In a patient with an acute gout flare and impaired renal function (eGFR 33 mL/min/1.73 m²) who cannot receive additional colchicine, what medication should be given?

Corticosteroids

In a patient with an acute gout flare, eGFR 33 mL/min/1.73 m², and contraindication to additional colchicine, give oral corticosteroids: prednisone 30-35 mg/day (or equivalent prednisolone) for 3-5 days. 1

Rationale for Corticosteroids in This Clinical Context

With an eGFR of 33 mL/min/1.73 m² (Stage 3b CKD approaching Stage 4), this patient has severe renal impairment that eliminates most first-line options:

• Colchicine is contraindicated: Both EULAR and ACR guidelines explicitly state colchicine should be avoided in severe renal impairment (GFR <30 mL/min) 1. At eGFR 33, you're at the threshold where colchicine clearance is significantly reduced, and the FDA label confirms treatment courses should be limited 2. Since the patient "cannot receive additional colchicine," this option is off the table.

• NSAIDs are contraindicated: EULAR guidelines explicitly state "colchicine and NSAIDs should be avoided in patients with severe renal impairment" 1. NSAIDs pose significant risks of acute kidney injury and cardiovascular events in CKD patients 3.

• Corticosteroids remain safe and effective: This leaves corticosteroids as the primary therapeutic option. The 2017 EULAR guidelines recommend oral corticosteroids at 30-35 mg/day of equivalent prednisolone for 3-5 days as a first-line option for acute flares 1. The 2012 ACR guidelines support oral prednisone 0.5 mg/kg per day for 5-10 days at full dose then stop, OR 2-5 days at full dose then taper for 7-10 days 4.

Specific Dosing Recommendations

Oral route (preferred):

• Prednisone or prednisolone 30-35 mg/day for 3-5 days 1
• Alternative: 0.5 mg/kg/day for 5-10 days, then stop or taper 4

Alternative routes if oral not feasible:

• Intra-articular corticosteroid injection (if monoarticular) 1
• Intramuscular triamcinolone acetonide 60 mg 4

Evidence Supporting Corticosteroids

The evidence base is robust: randomized trials demonstrate that prednisolone 35 mg/day for 5 days was equivalent to naproxen 500 mg twice daily, and prednisolone 30 mg/day for 5 days had analgesic effectiveness equivalent to indomethacin 1. Importantly, short-term corticosteroid use poses minimal risk and is particularly valuable when colchicine and NSAIDs are contraindicated 5, 3.

Common Pitfalls to Avoid

• Don't use low-dose corticosteroids (<10 mg/day): These doses are for prophylaxis, not acute flare treatment 4
• Don't extend duration unnecessarily: Keep to 3-5 days to minimize side effects
• Don't forget to monitor: Watch for hyperglycemia, hypertension exacerbation, and fluid retention—particularly relevant given CKD
• Don't attempt colchicine dose reduction: The FDA label and guidelines are clear that in severe renal impairment, even reduced colchicine doses carry toxicity risk 2

Second-Line Option: IL-1 Inhibitors

If corticosteroids fail or are contraindicated (e.g., uncontrolled diabetes, active infection), IL-1 blockers (canakinumab) should be considered 1. EULAR guidelines specifically recommend IL-1 blockers for patients with contraindications to colchicine, NSAIDs, and corticosteroids 1. Recent case reports demonstrate efficacy even in complex patients with CKD and multiple comorbidities 6, and clinical trials show canakinumab provides rapid pain relief in patients who cannot use conventional therapies 7.

However, IL-1 inhibitors are:

• Not first-line due to cost and availability
• Contraindicated if active infection present 1
• Require monitoring for serious infections

The practical algorithm: Start with oral corticosteroids immediately. Reserve IL-1 inhibitors for refractory cases or when corticosteroids are also contraindicated.